In accordance with the previous studies [48,49], we found that the level of anti-S1 IgA in COVID-19 patients was relatively high and was maintained over 9 months after infection (in over 70% and 80% of patients without pneumonia and with pneumonia, respectively). This evidence concerns the gene CD79A and COVID-19.